Google
AZN 株価分析 — ASTRAZENECA PLC (Healthcare >> Drug Manufacturers - General)
AZN に関するよくある質問
AZNのPER（株価収益率）は？
ASTRAZENECA PLC（AZN）は現在PER 25.81倍で取引されています。
AZNのROE（自己資本利益率）は？
ASTRAZENECA PLCのROEは20.73%です。
AZNの配当利回りは？
ASTRAZENECA PLCの配当利回りは1.26%です。
AZNの品質スコア（Quality Score）は？
当社のAIはAZNの総合財務品質を100点中92点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
AZNは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
AZNはどのセクターに属しますか？
ASTRAZENECA PLCはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE市場）
AZN AI Analysis Summary
Our AI summary for AZN: ASTRAZENECA PLC (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 25.81, ROE of 20.73%, a dividend yield of 1.26%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 169.64
Price
-1.70
(-0.99%)
Day Change
|
|
|---|
AZN, ファンダメンタルスコアはexcellent ( ファンダメンタル = 92) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROAがROEに比べて低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
54% |
| In Recommendations? | In "Invest - ROOKIE" Section |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
1233
|
| Magic Formula Rank by ROE |
1233
|
| Magic Formula Rank by ROIC |
1512
|
| Price | 169.64 |
| PBV / Sector |
5.34 / 2.68
|
| Earning Per Share | 6.57 |
| PE / Sector |
25.81 / 27.65
|
| PEG or PE/Growth / Sector |
0.53 / 0.28
GOOD
|
| Average 1M Daily Value |
469.65 M
GREAT
|
| Average 1W Daily Value |
457.47 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
52% |
| ポイントになる統計 |
|
72% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:31 |
| Symbol | AZN |
| Name | ASTRAZENECA PLC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 1,550.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 268,766.97 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
Phone: 44 20 3749 5000
Website: https://www.astrazeneca.com
Employees: 96,100
Description: AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
